1195768-23-0

Basic information

• Product Name: N-{3-[5-(2-chloro-4-pyriMidinyl)-2-(1,1-diethylethyl)-1,3-thiazol-4-yl]-2-fluoraphenyl}-2,6-difluorobenzenesulfonaMide
• Synonyms: N-{3-[5-(2-chloro-4-pyriMidinyl)-2-(1,1-diethylethyl)-1,3-thiazol-4-yl]-2-fluoraphenyl}-2,6-difluorobenzenesulfonaMide;N-{3-[5-(2-chloro-4-pyriMidinyl)-2-(1,1-diMethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonaMide;N-(3-(2-(tert-butyl)-5-(2-chloropyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
• CAS NO: 1195768-23-0
• Molecular Formula: C₂₃H₁₈ClF₃N₄O₂S₂
• Molecular Weight: 567.0459896
• EINECS: -0
• Mol File: 1195768-23-0.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 635.5±65.0 °C(Predicted)
• Appearance: /
• Density: 1.458±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 6.60±0.10(Predicted)
• CAS DataBase Reference: N-{3-[5-(2-chloro-4-pyriMidinyl)-2-(1,1-diethylethyl)-1,3-thiazol-4-yl]-2-fluoraphenyl}-2,6-difluorobenzenesulfonaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{3-[5-(2-chloro-4-pyriMidinyl)-2-(1,1-diethylethyl)-1,3-thiazol-4-yl]-2-fluoraphenyl}-2,6-difluorobenzenesulfonaMide(1195768-23-0)
• EPA Substance Registry System: N-{3-[5-(2-chloro-4-pyriMidinyl)-2-(1,1-diethylethyl)-1,3-thiazol-4-yl]-2-fluoraphenyl}-2,6-difluorobenzenesulfonaMide(1195768-23-0)

Safety Data

• Hazardous Substances Data: 1195768-23-0(Hazardous Substances Data)

Usage

General Description

N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1,1-diethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide is a complex chemical compound. This chemical is composed of multiple constituent elements, including carbon, hydrogen, nitrogen, sulfur, fluorine, and chlorine. It has distinct thiazole, pyrimidine, and benzene rings within its structure. N-{3-[5-(2-chloro-4-pyriMidinyl)-2-(1,1-diethylethyl)-1,3-thiazol-4-yl]-2-fluoraphenyl}-2,6-difluorobenzenesulfonaMide belongs to the class of organic compounds known as benzenesulfonamides, which are organosulfur compounds that contain a sulfur atom connected to an amino group (NH2) and a benzene ring. Chemicals within this category are often used as diuretics, or other medicinal purposes. However, specific properties, behavior, or uses of this precise chemical are not generally described in available literature, suggesting that it may primarily be of interest for research or specialized industrial applications rather than wider commercial or medical use.

Upstream product

• 1195765-45-7 dabrafenib 
• 317-46-4 2-fluoro-3-nitro-benzoic acid 
• 437-86-5 2-fluoro-3-nitrotoluene 
• 946126-94-9 2-fluoro-3-nitrobenzoic acid methyl ester 
• 914223-43-1 3-amino-2-fluoro benzoic acid 
• 630-22-8 2,2-dimethylpropanethioamide 
• 161957-56-8 3-bromo-2-fluorobenzoic acid 
• 206551-41-9 2-fluoro-3-bromobenzoic acid methyl ester 
• 1195768-20-7 N-(3-(2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide 
• 1042055-86-6 methyl 3-((tert-butoxycarbonyl)amino)-2-fluorobenzoate 
• 1195768-19-4 3-(2,6-difluorobenzenesulfonamido)-2-fluorobenzoic acid methyl ester 
• 1195768-18-3 3-amino-2-fluorobenzoic acid methyl ester 
• 60230-36-6 2,6-difluorobenzene-1-sulfonyl chloride 

Downstream Products

• 1195765-45-7 dabrafenib 
• 1195768-06-9 N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonic acid 
• 1195767-33-9 N-[3-(2-(1,1-dimethylethyl)-5-{2-[2-(methylsulfonyl)ethyl]-4-pyrimidinyl}-1,3-thiazol-4-yl)-2-fluorophenyl]-2,6-difluorobenzenesulfonamide 
• 1195769-46-0 N-{3-[2-(1,1-dimethylethyl)-5-(2-ethenyl-4-pyrimidinyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide 
• 1195767-08-8 ethyl 3-{4-[4-(3-{[(2,6-difluorophenyl)sulfonyl]amino}-2-fluorophenyl)-2-(1,1-dimethylethyl)-1,3-thiazol-5-yl]-2-pyrimidinyl}propanoate 
• 1195767-29-3 N-(3-{2-(1,1-dimethylethyl)-5-[2-(3-hydroxypropyl)-4-pyrimidinyl]-1,3-thiazol-4-yl}-2-fluorophenyl)-2,6-difluorobenzenesulfonamide 
• 1195767-72-6 N-{3-[2-(1,1-dimethylethyl)-5-(2-{[(2R)-2-hydroxypropyl]amino}-4-pyrimidinyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide 
• 1195767-74-8 N-{3-[5-{2-[(2-cyanoethyl)amino]-4-pyrimidinyl}-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide 

Relevant articles and documents

Deaminative chlorination of aminoheterocycles

Selective modification of heteroatom-containing aromatic structures is in high demand as it permits rapid evaluation of molecular complexity in advanced intermediates. Inspired by the selectivity of deaminases in nature, herein we present a simple methodology that enables the NH2 groups in aminoheterocycles to be conceived as masked modification handles. With the aid of a simple pyrylium reagent and a cheap chloride source, C(sp2)?NH2 can be converted into C(sp2)?Cl bonds. The method is characterized by its wide functional group tolerance and substrate scope, allowing the modification of >20 different classes of heteroaromatic motifs (five- and six-membered heterocycles), bearing numerous sensitive motifs. The facile conversion of NH2 into Cl in a late-stage fashion enables practitioners to apply Sandmeyer- and Vilsmeier-type transforms without the burden of explosive and unsafe diazonium salts, stoichiometric transition metals or highly oxidizing and unselective chlorinating agents. [Figure not available: see fulltext.]

LIM KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN LIMK-MEDIATED DISEASES

The present invention relates to LIM Kinase inhibitors of Formula (I) and pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4, X1, X2, X3, Y1, Y2 and Z are as defined in the claims, and their use for the treatment and/or prevention of LIMK-mediated diseases.

PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER

The present disclosure pertains to a pharmaceutical combination comprising (a) alpha- isoform specific PI3K inhibitor and (b) a B-RAF inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.